Intercept’s liver disease drug faces full approval delay following negative adcomm

Fol­low­ing a near­ly unan­i­mous ad­comm against Al­fasig­ma and In­ter­cept Phar­ma­ceu­ti­cals’ rare liv­er dis­ease drug Ocali­va, the FDA has de­layed its de­ci­sion on whether to con­vert …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.